menu
    • menu

    Company profile for Egis Pharmaceuticals PLC

    Egis Pharmaceuticals PLC-PSE
    News
    Hungarian Pharma Giants May Begin Uzbekistan Production

    24 Jun 2025

    // PRESS RELEASE

    Egis & the University of Szeged Expand Their Cooperation

    05 Mar 2025

    // PRESS RELEASE

    Our project aimed at developing oncological active ingredients

    24 Feb 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Egis Pharmaceuticals

    Contact Supplier

    Website

    CPhI Korea

    Attending

    Book a meeting

    envelop Contact Supplier

    Latest Content

    radio-compass-blog/j-j-s-intra-cellular-buyout-bms-oncology-gambit-sanofi-s-blueprint-acquisition-drive-mega-deals-in-h1-2025

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    Key Products KEY PRODUCTS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Related CompaniesRelated Companies

    About

    Egis is a member of the Servier Group. Egis’ products are manufactured at 3 production sites in Hungary, which are certified by EMA,FDA, ANVISA, PMDA ,KFDA. Egis sells its products under Egis’ brand names in 18 countries. In total, the company’s APIs & finished products reach 100 countries. Egis’ focus lies on treating diseases of cardiovascular & central nervous systems; however, it also provides modern treatment solutions in the fields of diabetology, dermatology & wound care. Our research and development activities focus on high-quality, value-added branded generic products. From 2023, Egis offers its CDMO & CMO services as well.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Egis Pharmaceuticals PLCHungary Flag
    Country
    Country
    Hungary
    Address
    Address
    1106 Budapest, Keresztúri út 30-38
    Telephone
    Telephone
    +36 18035555
    Client Email
    Email
    mailbox@egis.hu
    Client Website
    Website
    https://int.egis.health/home
    Linkedin
    Linkedin
    https://www.linkedin.com/company/egis-pharmaceuticals-plc/
    youtube
    YouTube
    http://www.youtube.com/@EgisPharma-rs6qr
    Twitter
    Twitter
    Contact Info
    Others

    FDFs
    fpd.opr@egis.hu
    APIs
    bulk.opr@egis.hu
    Services:
    pharmaservices@egis.hu

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI South East Asia

    Not Confirmed

    envelop Contact Supplier

    CPhI South East Asia

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-plc-party-content-45654.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-plc-party-content-17043.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    FDF Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-plc-party-content-53968.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    API Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-plc-party-content-74381.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    APIs Under Development 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-plc-party-content-76800.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Pharma Services

    read-more

      https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-party-content-3618.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/egis-pharmaceuticals-plc-party-content-45225.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    During the second quarter (Q2) of 2025, contract development and manufacturing organizations (CDMOs) made substantial investments in specialized therapeutic manufacturing. The quarter also saw CDMOs pursue high-value, complex manufacturing niches, particularly in antibody-drug conjugates (ADCs), cell and gene therapies (CGTs) and oligonucleotides.Alongside these trends, Q2 also saw CDMOs strengthen their footprint in the United States amid concerns over rising tariffs and unpredictable trade policies being enforced by the Trump administration.Regeneron Pharmaceuticals committed over US$ 3 billion through a 10-year agreement with Fujifilm Diosynth Biotechnologies to nearly double its US manufacturing capacity for biologics. Under this agreement, Fujifilm will manufacture and supply drug products for Regeneron at its large-scale facility in Holly Springs, North Carolina.Thermo Fisher Scientific announced plans to invest an additional US$ 2 billion in the US over four years, reinforcing its manufacturing and R&D capabilities. With 64 facilities spread across 37 states, Thermo Fisher aims to bolster American innovation and competitiveness. Similarly, Piramal Pharma announced a US$ 90 million investment plan for expanding two facilities in the US, thereby bringing its total investment in the country to US$ 570 million. View CDMO Activity Tracker for Q2 2025 (Free Excel Available)Veranova, Carbogen lead ADC wave; Axplora doubles down on HPAPI production in ItalyThe quarter saw substantial investments in ADC manufacturing. Veranova announced a US$ 20 million investment in bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus. With this investment, Veranova will be able to provide a more comprehensive suite of services to its partners developing ADCs and other bioconjugates. Veranova’s total investment in the Devens facility now stands at over US$ 50 million. Swiss CDMO Carbogen announced a US$ 31 million co-investment with an unnamed Japanese investor to expand its capabilities across its Aarau and Neuland (Switzerland) facilities. The facility will address increasing demand for complex and high-value compounds such as ADC drug linkers.Axplora announced a further €35 million (US$ 41 million) expansion of its Farmabios site in Italy, doubling the facility to approximately 108,000 square meters by mid-2026. This investment raises its total spend on the site to over €80 million (US$ 94.05 million) since 2019, supporting the production of highly potent active pharmaceutical ingredients (HPAPIs). Farmabios now stands as a key hub in Axplora’s global CDMO network.Polish pharmaceutical manufacturer Polfa Tarchomin is positioning itself as a significant player in the European CDMO market through its investment in the Center for Development and Production of Highly Potent Drugs. This 12,000 square meter facility has two state-of-the-art production lines designed for filling vials and pre-filled syringes with an annual capacity of 26 million product units.Skyepharma’s projected annual revenues from oncology-linked activities touched €10 million (US$ 11.2 million). The CDMO’s facility in Saint-Quentin-Fallavier is equipped to handle cytotoxic and cytostatic compounds, and is one of the few facilities in France capable of managing HPAPIs for oral anticancer treatments. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Athena acquires Medipha Santé, Famar buys MiP Pharma’s German site to strengthen European footprintDuring the quarter, several CDMOs enhanced their strategic capabilities through M&As. Athena Pharmaceutiques acquired  Medipha Santé to build a fully integrated pharmaceutical services platform in Europe. Based in Paris, Athena has strengthened its commercial and regulatory toolbox by bringing aboard Medipha Santé’s 35-strong team, which supports over 100 partner organizations and files approximately 350 dossiers annually with ANSM and other European agencies. With this integration, Athena positions itself as a one-stop CDMO partner.With the acquisition of MiP Pharma’s sterile manufacturing site in Homburg, Germany, the Famar Group has expanded its capabilities in aseptic and lyophilized fill-and-finish operations. The acquisition has strengthened Famar’s position in sterile drug manufacturing. The CDMO now has seven manufacturing facilities in Europe.PCI Pharma Services’ acquisition of Ajinomoto Althea has established a world-class, large-scale manufacturing hub in the San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high-potent formulations such as ADCs. PCI Pharma is now amongst the few US-based CDMOs capable of comprehensive ADC manufacturing.Samsung Biologics’ strategic spinoff of its biosimilar business stood out as a significant corporate restructuring exercise during the quarter. The separation of Samsung Bioepis, tentatively renamed Samsung Epis Holdings, aims to enhance Samsung Biologics’ strategic focus and build client trust, as it eliminates potential conflicts between CDMO services and proprietary drug development. The move came after Samsung Biologics inked a contract worth 737.3 billion Korean won (US$ 518 million) with an undisclosed US pharmaceutical company.WuXi Biologics announced a US$ 167 million divestment of its German facility to Terumo and broke ground on a microbial production plant in China. National Resilience, which was launched five years ago as the US drug manufacturer dedicated to broadening access to medicines and protecting biopharma supply chains, said it is shuttering six of its 10 facilities. The company said the sites were “not being fully utilized.” View CDMO Activity Tracker for Q2 2025 (Free Excel Available) MilliporeSigma, Simtra form 5-year ADC alliance; Silexion partners Catalent for siRNA developmentMerck KGaA’s MilliporeSigma and Simtra struck a five-year strategic alliance, combining expertise across the ADC value chain to reduce development timelines and complexity for biopharmaceutical companies. Viralgen collaborated with Trogenix to rapidly scale product supply for TGX-007, an AAV gene therapy for glioblastoma (a type of cancer of the brain and spinal cord).  Silexion announced a collaboration with Catalent for small interfacing RNA (siRNA) development and manufacturing. Catalent’s Limoges (France) facility will conduct formulation development and clinical manufacturing for Silexion’s SIL204 candidate, supporting both systemic and intra-tumoral delivery formulations.Skyepharma’s collaboration with Eneapharm through the Skyehub platform aims to support the treatment of patients suffering from exocrine pancreatic insufficiency, including those affected by cystic fibrosis or pancreatic cancer. Orion Corporation reached an agreement with Shilpa Biocare for the distribution of recombinant human albumin in Europe.Meanwhile, Aenova announced the launch of its Aenovation program, an initiative designed to fast-track early development of pharmaceutical formulations. The program addresses the critical challenges of bioavailability and time-to-market faced by poorly soluble drug candidates. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Our view The quarter saw CDMO developments mimic the broader trends in the pharmaceutical industry, such as onshoring of critical manufacturing capabilities in the US, consolidation of specialized expertise through strategic partnerships, and the relentless focus on emerging therapeutic modalities that promise to transform patient care. With CDMOs continuing to invest in next-generation manufacturing capabilities, we expect the sector to play a crucial role in drug innovation. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 422

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint

    #PharmaFlow by PHARMACOMPASS
    10 Jul 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Hungarian Pharma Giants May Begin Uzbekistan Production
    Hungarian Pharma Giants May Begin Uzbekistan Production

    24 Jun 2025

    // PRESS RELEASE

    https://kun.uz/en/news/2025/05/27/hungarian-pharma-giants-may-launch-medicine-production-in-uzbekistan

    PRESS RELEASE
    24 Jun 2025
    Share Share
    Egis & the University of Szeged Expand Their Cooperation
    Egis & the University of Szeged Expand Their Cooperation

    05 Mar 2025

    // PRESS RELEASE

    https://int.egis.health/a/egis-pharmaceuticals-plc-and-the-university-of-szeged-expand-their-cooperation

    PRESS RELEASE
    05 Mar 2025
    Share Share
    Our project aimed at developing oncological active ingredients
    Our project aimed at developing oncological active ingredients

    24 Feb 2025

    // PRESS RELEASE

    https://int.egis.health/a/our-project-aimed-at-developing-oncological-active-ingredients-and-preparations-has-concluded-successfully

    PRESS RELEASE
    24 Feb 2025
    Share Share
    Development Of High-Value Onco Drugs For Personalized Therapies
    Development Of High-Value Onco Drugs For Personalized Therapies

    05 Feb 2025

    // PRESS RELEASE

    https://int.egis.health/a/en-tou4g

    PRESS RELEASE
    05 Feb 2025
    Share Share
    Egis is recognised as a Top Employer 2025 in Hungary
    Egis is recognised as a Top Employer 2025 in Hungary

    20 Jan 2025

    // PRESS RELEASE

    https://int.egis.health/a/egis-is-recognised-as-a-top-employer-2025-in-hungary

    PRESS RELEASE
    20 Jan 2025
    Share Share
    Egis Pharma Expands Its Portfolio with a Well-Known Product Line
    Egis Pharma Expands Its Portfolio with a Well-Known Product Line

    16 Dec 2024

    // PRESS RELEASE

    https://int.egis.health/a/egis-pharmaceuticals-plc-expands-its-portfolio-with-a-well-known-product-line

    PRESS RELEASE
    16 Dec 2024
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Promethazine Hydrochloride

    Hungary

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Korea
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2021-06-10

    Pay. Date : 2021-06-07

    DMF Number : 7882

    Submission : 1989-01-24

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2008-279 - Rev 02

    Issue Date : 2023-01-12

    Type : Chemical

    Substance Number : 524

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 307MF10033

    Registrant's Address : H-1106 BUDAPEST KERESZTURI UT 30-38 HUNGARY

    Initial Date of Registration : 2025-02-07

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 48581-114

    Start Marketing Date : 2007-05-04

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF BR arrow-down
    ✖
    Available Reg. Filing : BR
    AUDIT
    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Allopurinol

    Hungary

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Korea
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2014-364 - Rev 01

    Issue Date : 2023-11-27

    Type : Chemical

    Substance Number : 576

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 231MF10077

    Registrant's Address : H-1106 BUDAPEST KERESZTURI UT 30-38 HUNGARY

    Initial Date of Registration : 2019-03-29

    Latest Date of Registration :

    EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : Masung LS Co., Ltd.

    Registration Date : 2021-01-25

    Registration Number : 20210125-209-J-511

    Manufacturer Name : EGIS Pharmaceuticals Plc.

    Manufacturer Address : Kereszturi ut 30-38., Budapest, 1106, Hungary

     VMF Others AUDIT
    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Chlorpromazine Hydrochloride

    Hungary

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Korea
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 1996-077 - Rev 07

    Issue Date : 2021-10-15

    Type : Chemical

    Substance Number : 475

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 304MF10157

    Registrant's Address : H-1106 BUDAPEST KERESZTURI UT 30-38 HUNGARY

    Initial Date of Registration : 2022-12-15

    Latest Date of Registration :

    EU-WC NDC KDMF VMF ASMF, BR arrow-down
    ✖
    Available Reg. Filing : ASMF, BR
    AUDIT
    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Ethacrynic Acid

    Hungary

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Korea
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 17193

    Submission : 2004-02-26

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2004-053 - Rev 01

    Issue Date : 2019-04-16

    Type : Chemical

    Substance Number : 457

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 48581-320

    Start Marketing Date : 2020-04-15

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT FOR ...

    KDMF VMF Others AUDIT
    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Allopurinol

    Hungary

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Korea
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 1996-032 - Rev 05

    Issue Date : 2019-08-09

    Type : Chemical

    Substance Number : 576

    Status : Valid

     JDMF EU-WC NDC KDMF VMF Others AUDIT
    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Amlodipine Besylate

    Hungary

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Korea
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2023-411 - Rev 00

    Issue Date : 2024-06-14

    Type : Chemical

    Substance Number : 1491

    Status : Valid

     JDMF EU-WC NDC KDMF arrow-down
    ✖

    Registrant Name : Korea Serviette Co., Ltd.

    Registration Date : 2016-03-23

    Registration Number : 20160323-130-H-293-45

    Manufacturer Name : EGIS PHARMACEUTICALS PRIVATE LIMITED COMPANY(Egis Pharmaceuticals PLC)

    Manufacturer Address : Site 1, H-1106 Budapest, X. Kereszturi Ut 30-38

     VMF CN, BR arrow-down
    ✖
    Available Reg. Filing : CN, BR
    AUDIT
    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Carvedilol

    Hungary

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Korea
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2016-314 - Rev 00

    Issue Date : 2023-08-28

    Type : Chemical

    Substance Number : 1745

    Status : Valid

     JDMF EU-WC NDC KDMF VMF Others AUDIT
    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Levomepromazine Maleate

    Hungary

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Korea
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2016-215 - Rev 01

    Issue Date : 2023-03-31

    Type : Chemical

    Substance Number : 925

    Status : Valid

     JDMF EU-WC NDC KDMF VMF ASMF, BR arrow-down
    ✖
    Available Reg. Filing : ASMF, BR
    AUDIT
    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Levomepromazine Maleate

    Hungary

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Korea
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 1997-058 - Rev 06

    Issue Date : 2023-03-20

    Type : Chemical

    Substance Number : 925

    Status : Valid

     JDMF EU-WC NDC KDMF VMF ASMF, BR arrow-down
    ✖
    Available Reg. Filing : ASMF, BR
    AUDIT
    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Methyldopa

    Hungary

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Korea
    Attending
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
    USDMF CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 1996-033 - Rev 07

    Issue Date : 2019-04-10

    Type : Chemical

    Substance Number : 45

    Status : Valid

     JDMF EU-WC NDC KDMF VMF Others AUDIT
    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    JDMF

    read-more
    read-more

    01

    Allopurinol

    Hungary
    arrow
    CPhI Korea
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Contact Supplier Contact Supplier
    Flag Hungary
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Egis Pharmaceuticals PLC

    Registration Number : 231MF10077

    Registrant's Address : H-1106 BUDAPEST KERESZTURI UT 30-38 HUNGARY

    Initial Date of Registration : 2019-03-29

    Latest Date of Registration : 2019-03-29

    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Carbidopa Hydrate

    Hungary
    arrow
    CPhI Korea
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Contact Supplier Contact Supplier
    Flag Hungary
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Egis Pharmaceuticals PLC

    Registration Number : 220MF10226

    Registrant's Address : H-1106 BUDAPEST KERESZTURI UT 30-38 HUNGARY

    Initial Date of Registration : 2008-11-10

    Latest Date of Registration : 2008-11-10

    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Chlorpromazine Hydrochloride

    Hungary
    arrow
    CPhI Korea
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Contact Supplier Contact Supplier
    Flag Hungary
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Egis Pharmaceuticals PLC

    Registration Number : 304MF10157

    Registrant's Address : H-1106 BUDAPEST KERESZTURI UT 30-38 HUNGARY

    Initial Date of Registration : 2022-12-15

    Latest Date of Registration : 2022-12-15

    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Promethazine Hydrochloride

    Hungary
    arrow
    CPhI Korea
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Contact Supplier Contact Supplier
    Flag Hungary
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Egis Pharmaceuticals PLC

    Registration Number : 307MF10033

    Registrant's Address : H-1106 BUDAPEST KERESZTURI UT 30-38 HUNGARY

    Initial Date of Registration : 2025-02-07

    Latest Date of Registration : 2025-02-07

    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Tofisopam

    Hungary
    arrow
    CPhI Korea
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothEgis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Contact Supplier Contact Supplier
    Flag Hungary
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Egis Pharmaceuticals PLC

    Registration Number : 219MF10297

    Registrant's Address : H-1106 BUDAPEST KERESZTURI UT 30-38 HUNGARY

    Initial Date of Registration : 2007-09-18

    Latest Date of Registration : 2021-09-28

    Egis Pharmaceuticals

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    API Manufacturing

    Discover their expertise for : API Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Egis Pharmaceuticals full-view
    Development of Chemical Intermediates
    full-view
    Small Molecule API Development Services
    full-view
    Intermediates for Anti-Cancer APIs
    full-view
    Highly Potent API (HPAPI) Manufacturing
    full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Egis Pharmaceuticals PLC and get a quotation

    Egis Pharmaceuticals PLC is a supplier offers 50 products (APIs, Excipients or Intermediates).

    Find a price of Promethazine Hydrochloride bulk with DMF, CEP, JDMF offered by Egis Pharmaceuticals PLC

    Find a price of Allopurinol bulk with CEP, JDMF offered by Egis Pharmaceuticals PLC

    Find a price of Chlorpromazine Hydrochloride bulk with CEP, JDMF offered by Egis Pharmaceuticals PLC

    Find a price of Ethacrynic Acid bulk with DMF, CEP offered by Egis Pharmaceuticals PLC

    Find a price of Allopurinol bulk with CEP offered by Egis Pharmaceuticals PLC

    Find a price of Amlodipine Besylate bulk with CEP offered by Egis Pharmaceuticals PLC

    Find a price of Aripiprazole bulk with CEP offered by Egis Pharmaceuticals PLC

    Find a price of Bisoprolol Fumarate bulk with CEP offered by Egis Pharmaceuticals PLC

    Find a price of Carbidopa bulk with JDMF offered by Egis Pharmaceuticals PLC

    Find a price of Carvedilol bulk with CEP offered by Egis Pharmaceuticals PLC

    Find a price of Duloxetine Hydrochloride bulk with CEP offered by Egis Pharmaceuticals PLC

    Find a price of Levomepromazine Maleate bulk with CEP offered by Egis Pharmaceuticals PLC

    Find a price of Methyldopa bulk with CEP offered by Egis Pharmaceuticals PLC

    Find a price of Quetiapine Hemifumarate bulk with CEP offered by Egis Pharmaceuticals PLC

    Find a price of Ramipril bulk with CEP offered by Egis Pharmaceuticals PLC

    Find a price of Tofisopam bulk with JDMF offered by Egis Pharmaceuticals PLC

    Find a price of Abemaciclib bulk offered by Egis Pharmaceuticals PLC

    Find a price of Abrocitinib bulk offered by Egis Pharmaceuticals PLC

    Find a price of Acalabrutinib bulk offered by Egis Pharmaceuticals PLC

    Find a price of Alectinib Hydrochloride bulk offered by Egis Pharmaceuticals PLC

    Find a price of Avapritinib bulk offered by Egis Pharmaceuticals PLC

    Find a price of Blarcamesine bulk offered by Egis Pharmaceuticals PLC

    Find a price of Carbadox bulk offered by Egis Pharmaceuticals PLC

    Find a price of Clomiphene Citrate bulk offered by Egis Pharmaceuticals PLC

    Find a price of Crotamiton bulk offered by Egis Pharmaceuticals PLC

    Find a price of Dapagliflozin Propanediol Monohydrate bulk offered by Egis Pharmaceuticals PLC

    Find a price of Deucravacitinib bulk offered by Egis Pharmaceuticals PLC

    Find a price of Donepezil bulk offered by Egis Pharmaceuticals PLC

    Find a price of Empagliflozin bulk offered by Egis Pharmaceuticals PLC

    Find a price of Entrectinib bulk offered by Egis Pharmaceuticals PLC

    Find a price of Etrasimod bulk offered by Egis Pharmaceuticals PLC

    Find a price of Fruquintinib bulk offered by Egis Pharmaceuticals PLC

    Find a price of Ketoprofen bulk offered by Egis Pharmaceuticals PLC

    Find a price of Levocetirizine Dihydrochloride bulk offered by Egis Pharmaceuticals PLC

    Find a price of Methoprene bulk offered by Egis Pharmaceuticals PLC

    Find a price of Nifedipine bulk offered by Egis Pharmaceuticals PLC

    Find a price of Nitrendipine bulk offered by Egis Pharmaceuticals PLC

    Find a price of Osimertinib Mesylate bulk offered by Egis Pharmaceuticals PLC

    Find a price of Ozanimod bulk offered by Egis Pharmaceuticals PLC

    Find a price of Palbociclib bulk offered by Egis Pharmaceuticals PLC

    Find a price of Pimavanserin Tartrate bulk offered by Egis Pharmaceuticals PLC

    Find a price of Resmetirom bulk offered by Egis Pharmaceuticals PLC

    Find a price of Ribociclib bulk offered by Egis Pharmaceuticals PLC

    Find a price of Rivaroxaban bulk offered by Egis Pharmaceuticals PLC

    Find a price of Sacubitril-Valsartan bulk offered by Egis Pharmaceuticals PLC

    Find a price of Solriamfetol Hydrochloride bulk offered by Egis Pharmaceuticals PLC

    Find a price of Tofisopam bulk offered by Egis Pharmaceuticals PLC

    Find a price of Troriluzole bulk offered by Egis Pharmaceuticals PLC

    Find a price of Upadacitinib bulk offered by Egis Pharmaceuticals PLC

    Find a price of Venetoclax bulk offered by Egis Pharmaceuticals PLC

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search